Hemophilia Market – Global Industry Analysis and Forecast (2022-2029)

Hemophilia Market is expected to reach USD 18.10 billion by 2029, with a CAGR of 5.5 % between 2022 and 2029. Hemophilia is a hereditary blood clotting illness that affects the capacity of the body to form clots. A person with haemophilia is more likely to bleed for a longer period of time following an injury, cut, or bruise, as well as an increased risk of bleeding inside joints or the brain. The report offers a comprehensive picture of the sector, using both qualitative and quantitative data. It gives a comprehensive analysis of the worldwide Hemophilia Market, as well as projections for the key categories. It also includes market size and forecast estimates for five key regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, for the years 2022 to 2029. The Hemophilia Market is further divided by countries and sectors within each location. Hemophilia MarketTo know about the Research Methodology :- Request Free Sample Report

Hemophilia Market Dynamics

Increased R&D efforts have come from the availability of restricted treatment therapy alternatives and the increased responsibility of regulatory authorities to address treatment. Both public and commercial healthcare organizations are substantially investing in the establishment of specialty clinics that are designed to satisfy patients' specific demands. In this context, the number of Hemophilia treatment centers is growing, with the goal of providing treatment to impoverished individuals. Authorities urge that persons with Hemophilia get therapy at a treatment facility for the best care and health education in order to stay healthy. Thus, the growth of the Hemophilia Market is expected to be fuelled by the construction of healthcare centers. One of the primary reasons driving the haemophilia market development is the increased prevalence of haemophilia, which is pushing up demand for treatment choices. Patients with severe haemophilia require a frequent haemophilia treatment program to keep enough clotting factors in their circulation to avoid bleeding. Hemophilia A affects 1 in every 5,000 male births in the United States, according to the Centers for Disease Control and Prevention. Because the number of dependent patients requiring excellent care is growing, this significant prevalence is expected to have a significant influence on the market. Additionally, patients who get quality care are more likely to have fewer co-morbid diseases and have a decreased risk of serious bleeding. As a result, as the number of patients with haemophilia continues to rise, so does the need for haemophilia therapy. As a result, the ever-increasing number of patients has increased the demand for haemophilia therapy, which will raise product adoption rates.

Hemophilia Market Segmentation Analysis

By Type, Hemophilia type A is the most common kind, with a prevalence of four times that of haemophilia type B. According to WebMD LLC figures published in 2021, the prevalence of type A varies by country, ranging from 5.4-to 14.5 instances per 100,000 males. Furthermore, around 50-60% of patients had severe haemophilia A, which is linked with severe bleeding symptoms. Moreover, the majority of available medicines are used to treat type A haemophilia. However, due to the availability of strong pipeline items, type B is expected to be the fastest-growing sector throughout the forecast period. Similarly, type B haemophilia accounts for around 20% of all haemophilia cases worldwide, with 50% of them having factor IX levels greater than 1%. By Therapy: The haemophilia market is divided into two segments based on therapy: prophylactic and on-demand medication. Prophylaxis was expected to be the fastest-growing sector throughout the forecast period, with on-demand holding the biggest market share in 2021. Prophylaxis is a regular infusion of clotting factor concentrates used in individuals with severe haemophilia. It is a largely acknowledged treatment among patients, resulting in a high rate of growth. The length of therapy is determined by the severity of the patients. Additionally, prophylactic therapy is expected to prevent productivity loss while improving quality of life.

Hemophilia MarketHemophilia Market Regional Insight

By 2029, the North American market is estimated to be worth USD 8.26 billion. The changing preference for prophylactic medical care among people living in this region is likely to contribute significantly to market growth. Owing to increased awareness and better healthcare infrastructure, the Asia Pacific market is expected to remain the fastest expanding market between 2021 and 2029, with a CAGR of 5.6 percent. A surge in per capita healthcare expenditure and improved healthcare infrastructure in developing countries such as India and China is likely to drive significant growth. Report Objectives: • Landscape analysis of the Hemophilia Market • competitive benchmarking • Past and current status of the industry with the forecasted market size and trends • Evaluation of potential key players that include market leaders, followers, and new entrants • Technology trends • The potential impact of micro-economic factors on the market • External and Internal factors affecting the market have been analyzed The report also helps in understanding the Hemophilia Market dynamics, and structure by analyzing the market segments to project the Hemophilia Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Hemophilia Market make the report investor’s guide.

Hemophilia Market Scope: Inquiry Before Buying

Hemophilia Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 11.80 Bn
Forecast Period 2022 to 2029 CAGR: 5.5 % Market Size in 2029: US $ 18.10 Bn.
Segments Covered: by Type  • Hemophilia A • Hemophilia B • Hemophilia C • Others
by Treatment • On-demand • Prophylaxis
by Therapy  • Replacement therapy • ITI therapy • Gene therapy

Hemophilia Market, by Region

• North America • Europe • Asia pacific • The Middle East and Africa • South America

Hemophilia Market, Key Players

• Bayer AG • Bio Marin Pharmaceutical, Inc. • CSL Behring • Kedrion • Novo Nordisk • Pfizer, Inc. • Roche (Chugai Pharmaceutical Co.) • Sanofi (Genzyme Corporation) • Takeda Pharmaceutical (Shire Plc) • Shire (Baxalta) • Spark Therapeutics, Inc. • Genzyme Corporation • Chugai Pharmaceutical Co. Ltd. • Novo Nordisk A/S. • Octapharma AG Frequently Asked Questions 1. What is the projected market size & growth rate of the Hemophilia Market? Ans- the Hemophilia Market was valued at USD 11.80 billion in 2021 and is projected to reach USD 18.10 billion by 2029, growing at a CAGR of 5.5 % during the forecast period. 2. What is the key driving factor for the growth of the Hemophilia Market? Ans- One of the primary reasons driving the haemophilia market development is the increased prevalence of haemophilia, which is pushing up demand for treatment choices. 3. Which Region accounted for the largest Hemophilia Market share? Ans- North America is accounted for the largest Hemophilia Market share. 4. What are the segments involved in the market’s segmental analysis?? Ans- Type, Treatment, and Therapy are the major segments in the market analysis. 5. What are the top players operating in the Hemophilia Market? Ans- Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion, Novo Nordisk, Pfizer, Inc.
1. Hemophilia Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Hemophilia Market: Qualitative Analysis 2.1. Technological Innovations Hemophilia Treatment 3. Hemophilia Market: Dynamics 3.1. Hemophilia Market Trends by Region 3.1.1. North America Hemophilia Market Trends 3.1.2. Europe Hemophilia Market Trends 3.1.3. Asia Pacific Hemophilia Market Trends 3.1.4. Middle East and Africa Hemophilia Market Trends 3.1.5. South America Hemophilia Market Trends 3.2. Hemophilia Market Dynamics by Region 3.2.1. North America 3.2.1.1. North America Hemophilia Market Drivers 3.2.1.2. North America Hemophilia Market Restraints 3.2.1.3. North America Hemophilia Market Opportunities 3.2.1.4. North America Hemophilia Market Challenges 3.2.2. Europe 3.2.2.1. Europe Hemophilia Market Drivers 3.2.2.2. Europe Hemophilia Market Restraints 3.2.2.3. Europe Hemophilia Market Opportunities 3.2.2.4. Europe Hemophilia Market Challenges 3.2.3. Asia Pacific 3.2.3.1. Asia Pacific Hemophilia Market Drivers 3.2.3.2. Asia Pacific Hemophilia Market Restraints 3.2.3.3. Asia Pacific Hemophilia Market Opportunities 3.2.3.4. Asia Pacific Hemophilia Market Challenges 3.2.4. Middle East and Africa 3.2.4.1. Middle East and Africa Hemophilia Market Drivers 3.2.4.2. Middle East and Africa Hemophilia Market Restraints 3.2.4.3. Middle East and Africa Hemophilia Market Opportunities 3.2.4.4. Middle East and Africa Hemophilia Market Challenges 3.2.5. South America 3.2.5.1. South America Hemophilia Market Drivers 3.2.5.2. South America Hemophilia Market Restraints 3.2.5.3. South America Hemophilia Market Opportunities 3.2.5.4. South America Hemophilia Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.5. Regulatory Landscape by Region 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 3.6. Key Opinion Leader Analysis For Hemophilia Industry 3.7. Analysis of Government Schemes and Initiatives For Hemophilia Industry 3.8. The Global Pandemic Impact on Hemophilia Market 4. Hemophilia Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 4.1. Hemophilia Market Size and Forecast, by Type (2023-2030) 4.1.1. Hemophilia A 4.1.2. Hemophilia B 4.1.3. Hemophilia C 4.1.4. Others 4.2. Hemophilia Market Size and Forecast, by Treatment (2023-2030) 4.2.1. On-demand 4.2.2. Prophylaxis 4.3. Hemophilia Market Size and Forecast, by Therapy (2023-2030) 4.3.1. Replacement therapy 4.3.2. ITI therapy 4.3.3. Gene therapy 4.4. Hemophilia Market Size and Forecast, by Region (2023-2030) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America Hemophilia Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 5.1. North America Hemophilia Market Size and Forecast, by Type (2023-2030) 5.1.1. Hemophilia A 5.1.2. Hemophilia B 5.1.3. Hemophilia C 5.1.4. Others 5.2. North America Hemophilia Market Size and Forecast, by Treatment (2023-2030) 5.2.1. On-demand 5.2.2. Prophylaxis 5.3. North America Hemophilia Market Size and Forecast, by Therapy (2023-2030) 5.3.1. Replacement therapy 5.3.2. ITI therapy 5.3.3. Gene therapy 5.4. North America Hemophilia Market Size and Forecast, by Country (2023-2030) 5.4.1. United States 5.4.1.1. United States Hemophilia Market Size and Forecast, by Type (2023-2030) 5.4.1.1.1. Hemophilia A 5.4.1.1.2. Hemophilia B 5.4.1.1.3. Hemophilia C 5.4.1.1.4. Others 5.4.1.2. United States Hemophilia Market Size and Forecast, by Treatment (2023-2030) 5.4.1.2.1. On-demand 5.4.1.2.2. Prophylaxis 5.4.1.3. United States Hemophilia Market Size and Forecast, by Therapy (2023-2030) 5.4.1.3.1. Replacement therapy 5.4.1.3.2. ITI therapy 5.4.1.3.3. Gene therapy 5.4.2. Canada 5.4.2.1. Canada Hemophilia Market Size and Forecast, by Type (2023-2030) 5.4.2.1.1. Hemophilia A 5.4.2.1.2. Hemophilia B 5.4.2.1.3. Hemophilia C 5.4.2.1.4. Others 5.4.2.2. Canada Hemophilia Market Size and Forecast, by Treatment (2023-2030) 5.4.2.2.1. On-demand 5.4.2.2.2. Prophylaxis 5.4.2.3. Canada Hemophilia Market Size and Forecast, by Therapy (2023-2030) 5.4.2.3.1. Replacement therapy 5.4.2.3.2. ITI therapy 5.4.2.3.3. Gene therapy 5.4.3. Mexico 5.4.3.1. Mexico Hemophilia Market Size and Forecast, by Type (2023-2030) 5.4.3.1.1. Hemophilia A 5.4.3.1.2. Hemophilia B 5.4.3.1.3. Hemophilia C 5.4.3.1.4. Others 5.4.3.2. Mexico Hemophilia Market Size and Forecast, by Treatment (2023-2030) 5.4.3.2.1. On-demand 5.4.3.2.2. Prophylaxis 5.4.3.3. Mexico Hemophilia Market Size and Forecast, by Therapy (2023-2030) 5.4.3.3.1. Replacement therapy 5.4.3.3.2. ITI therapy 5.4.3.3.3. Gene therapy 6. Europe Hemophilia Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 6.1. Europe Hemophilia Market Size and Forecast, by Type (2023-2030) 6.2. Europe Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.3. Europe Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4. Europe Hemophilia Market Size and Forecast, by Country (2023-2030) 6.4.1. United Kingdom 6.4.1.1. United Kingdom Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.1.2. United Kingdom Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.1.3. United Kingdom Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.2. France 6.4.2.1. France Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.2.2. France Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.2.3. France Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.3. Germany 6.4.3.1. Germany Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.3.2. Germany Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.3.3. Germany Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.4. Italy 6.4.4.1. Italy Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.4.2. Italy Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.4.3. Italy Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.5. Spain 6.4.5.1. Spain Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.5.2. Spain Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.5.3. Spain Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.6. Sweden 6.4.6.1. Sweden Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.6.2. Sweden Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.6.3. Sweden Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.7. Austria 6.4.7.1. Austria Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.7.2. Austria Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.7.3. Austria Hemophilia Market Size and Forecast, by Therapy (2023-2030) 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe Hemophilia Market Size and Forecast, by Type (2023-2030) 6.4.8.2. Rest of Europe Hemophilia Market Size and Forecast, by Treatment (2023-2030) 6.4.8.3. Rest of Europe Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7. Asia Pacific Hemophilia Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 7.1. Asia Pacific Hemophilia Market Size and Forecast, by Type (2023-2030) 7.2. Asia Pacific Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.3. Asia Pacific Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4. Asia Pacific Hemophilia Market Size and Forecast, by Country (2023-2030) 7.4.1. China 7.4.1.1. China Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.1.2. China Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.1.3. China Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.2. S Korea 7.4.2.1. S Korea Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.2.2. S Korea Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.2.3. S Korea Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.3. Japan 7.4.3.1. Japan Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.3.2. Japan Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.3.3. Japan Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.4. India 7.4.4.1. India Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.4.2. India Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.4.3. India Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.5. Australia 7.4.5.1. Australia Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.5.2. Australia Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.5.3. Australia Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.6. Indonesia 7.4.6.1. Indonesia Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.6.2. Indonesia Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.6.3. Indonesia Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.7. Malaysia 7.4.7.1. Malaysia Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.7.2. Malaysia Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.7.3. Malaysia Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.8. Vietnam 7.4.8.1. Vietnam Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.8.2. Vietnam Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.8.3. Vietnam Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.9. Taiwan 7.4.9.1. Taiwan Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.9.2. Taiwan Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.9.3. Taiwan Hemophilia Market Size and Forecast, by Therapy (2023-2030) 7.4.10. Rest of Asia Pacific 7.4.10.1. Rest of Asia Pacific Hemophilia Market Size and Forecast, by Type (2023-2030) 7.4.10.2. Rest of Asia Pacific Hemophilia Market Size and Forecast, by Treatment (2023-2030) 7.4.10.3. Rest of Asia Pacific Hemophilia Market Size and Forecast, by Therapy (2023-2030) 8. Middle East and Africa Hemophilia Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 8.1. Middle East and Africa Hemophilia Market Size and Forecast, by Type (2023-2030) 8.2. Middle East and Africa Hemophilia Market Size and Forecast, by Treatment (2023-2030) 8.3. Middle East and Africa Hemophilia Market Size and Forecast, by Therapy (2023-2030) 8.4. Middle East and Africa Hemophilia Market Size and Forecast, by Country (2023-2030) 8.4.1. South Africa 8.4.1.1. South Africa Hemophilia Market Size and Forecast, by Type (2023-2030) 8.4.1.2. South Africa Hemophilia Market Size and Forecast, by Treatment (2023-2030) 8.4.1.3. South Africa Hemophilia Market Size and Forecast, by Therapy (2023-2030) 8.4.2. GCC 8.4.2.1. GCC Hemophilia Market Size and Forecast, by Type (2023-2030) 8.4.2.2. GCC Hemophilia Market Size and Forecast, by Treatment (2023-2030) 8.4.2.3. GCC Hemophilia Market Size and Forecast, by Therapy (2023-2030) 8.4.3. Nigeria 8.4.3.1. Nigeria Hemophilia Market Size and Forecast, by Type (2023-2030) 8.4.3.2. Nigeria Hemophilia Market Size and Forecast, by Treatment (2023-2030) 8.4.3.3. Nigeria Hemophilia Market Size and Forecast, by Therapy (2023-2030) 8.4.4. Rest of ME&A 8.4.4.1. Rest of ME&A Hemophilia Market Size and Forecast, by Type (2023-2030) 8.4.4.2. Rest of ME&A Hemophilia Market Size and Forecast, by Treatment (2023-2030) 8.4.4.3. Rest of ME&A Hemophilia Market Size and Forecast, by Therapy (2023-2030) 9. South America Hemophilia Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 9.1. South America Hemophilia Market Size and Forecast, by Type (2023-2030) 9.2. South America Hemophilia Market Size and Forecast, by Treatment (2023-2030) 9.3. South America Hemophilia Market Size and Forecast, by Therapy (2023-2030) 9.4. South America Hemophilia Market Size and Forecast, by Country (2023-2030) 9.4.1. Brazil 9.4.1.1. Brazil Hemophilia Market Size and Forecast, by Type (2023-2030) 9.4.1.2. Brazil Hemophilia Market Size and Forecast, by Treatment (2023-2030) 9.4.1.3. Brazil Hemophilia Market Size and Forecast, by Therapy (2023-2030) 9.4.2. Argentina 9.4.2.1. Argentina Hemophilia Market Size and Forecast, by Type (2023-2030) 9.4.2.2. Argentina Hemophilia Market Size and Forecast, by Treatment (2023-2030) 9.4.2.3. Argentina Hemophilia Market Size and Forecast, by Therapy (2023-2030) 9.4.3. Rest Of South America 9.4.3.1. Rest Of South America Hemophilia Market Size and Forecast, by Type (2023-2030) 9.4.3.2. Rest Of South America Hemophilia Market Size and Forecast, by Treatment (2023-2030) 9.4.3.3. Rest Of South America Hemophilia Market Size and Forecast, by Therapy (2023-2030) 10. Global Hemophilia Market: Competitive Landscape 10.1. MMR Competition Matrix 10.2. Competitive Landscape 10.3. Key Players Benchmarking 10.3.1. Company Name 10.3.2. Business Segment 10.3.3. End-user Segment 10.3.4. Revenue (2023) 10.3.5. Company Locations 10.4. Leading Hemophilia Market Companies, by market capitalization 10.5. Market Structure 10.5.1. Market Leaders 10.5.2. Market Followers 10.5.3. Emerging Players 10.6. Mergers and Acquisitions Details 11. Company Profile: Key Players 11.1. Bayer AG 11.1.1. Company Overview 11.1.2. Business Portfolio 11.1.3. Financial Overview 11.1.4. SWOT Analysis 11.1.5. Strategic Analysis 11.1.6. Recent Developments 11.2. Bio Marin Pharmaceutical, Inc. 11.3. CSL Behring 11.4. Kedrion 11.5. Novo Nordisk 11.6. Pfizer, Inc. 11.7. Roche (Chugai Pharmaceutical Co.) 11.8. Sanofi (Genzyme Corporation) 11.9. Takeda Pharmaceutical (Shire Plc) 11.10. Shire (Baxalta) 11.11. Spark Therapeutics, Inc. 11.12. Genzyme Corporation 11.13. Chugai Pharmaceutical Co. Ltd. 11.14. Novo Nordisk A/S. 11.15. Octapharma AG 12. Key Findings 13. Industry Recommendations 14. Hemophilia Market: Research Methodology 15. Terms and Glossary

About This Report

Report ID 67045
Category Healthcare
Published Date December 2023
Updated Date
  • INQUIRE BEFORE BUYING